Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment

Journal of Infection

Volumn 66, Issue 4, 2013, Pages 346-356

  Bartalesi, Filippo ^a   Goletti, Delia ^b   Spinicci, Michele ^c   Cavallo, Annalisa ^a   Attala, Letizia ^c   Mencarini, Jessica ^c   Fiori, Ginevra ^a   Li Gobbi, Francesca ^d   Mantella, Antonia ^c   Benucci, Maurizio ^d   Prignano, Francesca ^c   Pimpinelli, Nicola ^c   Matucci Cerinic, Marco ^a,c   Girardi, Enrico ^b   Bartoloni, Alessandro ^a,c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Interferon release assay; Latent tuberculosis infection therapy; QuantiFERON TB Gold; Rheumatic diseases; Tumor necrosis factor inhibitors

Indexed keywords

GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE COURSE; FEMALE; HUMAN; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; RISK FACTOR; SCORING SYSTEM; T LYMPHOCYTE; TUBERCULOSIS;

AGED; ANTIGENS, BACTERIAL; FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875505513     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.017     Document Type: Article

References (44)

1. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
2. Gardam M.A., Keystone E.C., Menzies R., Manners S., Skamene E., Long R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3(3):148-155.
3. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8(10):601-611.
4. Valesini G., Montecucco C., Cutolo M. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 2006, 24(4):413-423.
5. Solovic I., Sester M., Gomez-Reino J.J., Rieder H.L., Ehlers S., Milburn H.J., et al. The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement. Eur Respir J 2010, 36:1185-1206.
6. Mazurek M., Jereb J., Vernon A., LoBue P., Goldberg S., Castro K., et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010, 59(RR-5):1-25.
7. National Institute for Health and Clinical Excellence Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control July 24 2012, [last accessed 30.07.12]. http://www.nice.org.uk/guidance/CG117.
8. Bartalesi F., Vicidomini S., Goletti D., Fiorelli C., Fiori G., Melchiorre D., et al. QuantiFERON-TB gold and TST are both useful for latent TB screening in autoimmune diseases. Eur Respir J 2009, 33:1-8.
9. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149(3):177-184.
10. Andersen P., Munk M.E., Pollock J.M., Doherty T.M. Specific immune-based diagnosis of tuberculosis. Lancet 2000, 356:1099-1104.
11. Chee C.B.E., Barkham T.M.S., KhinMar K.W., Gan S.H., Wang Y.T. Quantitative T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens in active and latent tuberculosis. Eur J Clin Microbiol Infect Dis 2009, 28:667-670.
12. Sauzullo I., Mengoni F., Lichtner M., Massetti A.P., Rossi R., Iannetta M., et al. In vivo and in vitro effects of anti-tuberculosis treatment on mycobacterial interferon-gamma T-cell response. PLoS One 2009, 4(4):e5187.
13. Aiken A.M., Hill P.C., Fox A., McAdam K.P., Jackson-Sillah D., Lugos M.D., et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006, 6:66.
14. Carrara S., Vincenti D., Petrosillo N., Amicosante M., Girardi E., Goletti D. Use of a T-cell based assay for monitoring efficacy of anti-tuberculosis therapy. Clin Infect Dis 2004, 38:754-756.
15. Butera O., Chiacchio T., Carrara S., Casetti R., Vanini V., Meraviglia S., et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis 2009, 9:182.
16. Kabeer B.S., Raja A., Raman B., Thangaraj S., Leportier M., Ippolito G., et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011, 11:135.
17. Goletti D, Parracino MP, Butera O, Bizzoni F, Casetti R, Dainotto D, et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res.
18. Herrmann JL, Belloy M, Porcher R, Simonney N, Aboutaam R, Lebourgeois M, et al. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS One.
19. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, et al. Persistently elevated T-cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol.
20. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med.
21. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med.
22. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G, et al. Effect of treatment of latent tuberculosis infection on the T-cell response to Mycobacterium tuberculosis antigens. J Infect Dis.
23. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology.
24. Lee S.H., Lew W.J., Kim H.J., Lee H.K., Lee Y.M., Cho C.H., et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respir Med 2010, 104(3):448-453.
25. Dyrhol-Riise A.M., Gran G., Wentzel-Larsen T., Blomberg B., Haanshuus C.G., Mørkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB gold in-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010, 10:57.
26. Chen D.Y., Shen G.H., Chen Y.M., Chen H.H., Hsieh C.W., Lan J.L. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay. Ann Rheum Dis 2012 Feb, 71(2):231-237.
27. Furst D.E., Keystone E.C., Braun J., Smolen J.S., Burmester G.R., Emery P., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012, 71(Suppl. 2):i2-i45.
28. Jasmer R.M., Nahid P., Hopewell P.C. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002, 347(23):1860-1866.
29. Sgountzos V., Simopoulou S., Kretsou S., Sakayianni K., Pavlerou S., Gourgoulianis K., et al. Comparative study of RT23 and Merieux tuberculin tested among healthy volunteers. Int J Tuberc Lung Dis 2009, 13(3):312-316.
30. American Thoracic Society Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161(4 Pt 2):S221-S247.
31. Pai M., Joshi R., Dogra S., Zwerling A.A., Gajalakshmi D., Goswami, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009, 13(1):84-92.
32. Harada N., Higuchi K., Sekiya Y., Rothel J., Kitoh T., Mori T. Basic characteristics of a novel diagnostic method (QuantiFERON TB-2G) for latent tuberculosis infection with the use of Mycobacterium tuberculosis-specific antigens, ESAT-6 and CFP-10. Kekkaku 2004, 79:725-735. [Japanese].
33. Bélard E., Semb S., Ruhwald M., Werlinrud A.M., Soborg B., Jensen F.K., et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011, 17(11):2340-2349.
34. Franken W.P., Arend S.M., Thijsen S.F., Bouwman J.J., Koster B.F., van Dissel J.T., et al. Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts. Int J Tuberc Lung Dis 2008, 12(11):1286-1294.
35. van Zyl-Smit R.N., Zwerling A., Dheda K., Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009, 4(12):e8517.
36. Perry S., Sanchez L., Yang S., Agarwal Z., Hurst P., Parsonnet Reproducibility of QuantiFERON-TB gold in-tube assay. J Clin Vaccine Immunol 2008, 15(3):425-432.
37. Goletti D., Carrara S., Mayanja-Kizza H., Baseke J., Mugerwa M.A., Girardi E., et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect Dis 2008, 28(8):11.
38. Leidl L., Mayanja-Kizza H., Sotgiu G., Baseke J., Ernst M., Hirsch C., et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J 2010, 35(3):619-626.
39. Goletti D., Raja A., Syed Ahamed Kabeer B., Rodrigues C., Sodha A., Carrara S., et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?. PLoS One 2010, 5(9):e12577.
40. Delogu G., Chiacchio T., Vanini V., Butera O., Cuzzi G., Bua A., et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS One 2011, 6(3):e18315.
41. Goletti D., Butera O., Vanini V., Lauria F.N., Lange C., Franken K.L., et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010, 36(1):135-142.
42. Chiacchio T., Petruccioli E., Vanini V., Butera O., Cuzzi G., Petrone L., et al. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One 2011, 6(11):e27539.
43. Vanini V., Petruccioli E., Gioia C., Cuzzi G., Orchi N., Rianda A., et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012, 65(1):49-59.
44. Diel R., Goletti D., Ferrara G., Bothamley G., Cirillo D., Kampmann B., et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37(1):88S-99S.